Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:5/27/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, May 27 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 (dirucotide) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the fourth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 (dirucotide) in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 (dirucotide) versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for an $87 million upfront payment, milestone paymen
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Leading Regenerative Veterinary Medicine ... allogeneic stem-cell product development program and changes its’ ... corporate strategic direction. , “I am extremely pleased ... cell development program has been kicked into high ... facility and hiring of our new Director of ...
(Date:4/24/2015)... Telbec/ - Mirego, leader in mobile strategies and solutions, is ... app extensions for the all new Apple Watch. Made in ... and MediaMiser, these extensions will reinvent the way users receive ... wrist use.  Available today in ... tactile smartwatch that makes for an excellent buddy for business, ...
(Date:4/23/2015)... Marshall, MN (PRWEB) April 24, 2015 ... agreement with Advanced Birthright Nutrition® (ABN) for the exclusive ... Milk Cup. The new technology is a new in-line ... swine producers by allowing them to move supplementation milk ... running. , “This technology lets producers get ...
(Date:4/23/2015)... , April 23, 2015 BioTE Medical President ... book "Age Healthier Live Happier - Avoiding Over-Medication through ... Age Management Medicine Group Conference at JW Marriott / ... ",Age Healthier Live Happier, is a welcomed ... over-medication and searching for a higher quality of life ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Ralco Acquires License to Birthright™ Moveable Milk Cup 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3
... and SHP Parakrama Karunaratne, Dept. of Medical,Parasitology, London School of Hygiene and Tropical Medicine, ... , Introduction , ... a worldwide vector of , diseases such ... are sprayed with organophosphate insecticides. However, mosquitoes develop , ...
... Brian J. Shiell and Wojtek P. Michalski, CSIRO Division of ... , Introduction ... composition analyses of proteins can be performed , ... the most commonly used method of recovering proteins from gels, can ...
... and William S. Dalton,H. Lee Moffitt Cancer Center and Research Institute, University of ... , ... mutations within specific genes has become an important , ... , including cancer. Several techniques have ...
Cached Biology Technology:Preparative Nondenaturing Gel Electrophoresis Used in the Purification of an Esterase Involved in Insecticide Resistance, Rev C 2Preparative Nondenaturing Gel Electrophoresis Used in the Purification of an Esterase Involved in Insecticide Resistance, Rev C 3Fractionation of Bovicola ovis Homogenates Using the Mini Whole Gel Eluter 2Fractionation of Bovicola ovis Homogenates Using the Mini Whole Gel Eluter 3Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 2Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 3Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 4Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 5
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... used an innovative inkjet system to print unique "bio-ink" ... to differentiate into both muscle cells and bone cells. ... system that can pattern the formation of multiple tissues ... , Bioengineers from Carnegie Mellon University’s Robotics Institute ...
... have discovered a better way to see where a drug ... novel hollow platinum nanostructures. , The research will appear as ... journal Angewandte Chemie Int. Ed. In advance of publication, it ... web site. , Sandia is a National Nuclear Security ...
... by researchers at the University at Buffalo has been shown ... tumors and to inhibit the cancer's spread to the lungs ... antibody, named JAA-F11, targets a particular disaccharide, an antigen known ... cancer cells. While the antibody did not kill the ...
Cached Biology News:Muscle and bone from an ink-jet printer 2Sandia researchers discover way to see how a drug attaches to a cell 2Antibody extends life of mice with breast cancer 2
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
... UNOsphere ion exchange ... supports with high binding ... support is a strong ... particle size of 120 ...
...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S ... The gamma secretase is a multiprotein ... and Pen-2; all four proteins are ... gamma secretase complex catalyzes cleavage of ...
Biology Products: